Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of ABP 938 versus aflibercept in neovascular age-related macular degeneration
MOH_2020-10-01_009289Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- May 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 and aflibercept in exudative macular degeneration (3 arms), sponsored by Amgen. Planned start May 2020; status: not yet recruiting.
02
Drugs
9MW0813aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2020-10-01_009289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-01_009289.